Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

The step reflects Takeda's strategic commitment to Asia and to China in particular. Takeda is now enhancing its business in China through TCH's wholly owned subsidiaries, Takeda Pharmaceutical (China) in Taizhou, responsible for manufacturing, and Tianjin Takeda Pharmaceuticals in Tianjin, responsible for marketing and sales. With them, TSDC will help drive Takeda's growth agenda in China and in the broader Asian region.

Within Asia outside Japan, including China, drug development is overseen by Takeda Global Research & Development Center (Asia) in Singapore and Millennium Pharmaceuticals in Cambridge, Mass., wholly owned subsidiaries of Takeda, through outsourcing to CROs. TSDC will work to extend the company's clinical development activities within Asia, with a focus on China for general medicine and across Asia for Oncology. The team will be composed of personnel from both the Pharmaceutical Development Division and Millennium.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private á¼€nancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs